Dateline City:
DURHAM, N.C.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture bulk varicella at the companys site in Durham, N.C., for use in Mercks vaccines to protect against chickenpox and shingles. The approval will enable the site to produce bulk varicella supply for the U.S. and help boost Mercks overall global supply capabilities.
In 2010, the site was approved to produce finished chickenpox vaccines.
Language:
English
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more